Urinary F2-Isoprostanes and Metabolic Markers of Fat Oxidation
Table 1
Characteristics of the study population ( = 682).
Characteristics
Mean (SD) or number (%)
Age (years)
54.5 (8.4)
Sex, female (number, %)
385 (56.5)
Ethnicity (number, %)
Non-Hispanic White
291 (43)
African American
174 (25)
Hispanic White
217 (32)
Normal glucose tolerance, NGT (number, %)
226 (33)
Impaired glucose tolerance IGT (number, %)
456 (67)
BMI (kg/m2)
Normal (<25)
179 (26)
Overweight (25–29.9)
303 (44)
Obese (≥30)
199 (29)
Missing
1
iPF2α-III (ng/mg creatinine)
0.25 (0.20)
2,3-dinor-iPF2-III (ng/mg creatinine)
4.32 (3.05)
iPF2-VI (ng/mg creatinine)
6.46 (4.08)
8,12-iso-iPF2α-VI (ng/mg creatinine)
4.19 (2.92)
F2-isoprostane composite index
1.41 (0.80)
Acetylcarnitine, C2 (nmole/g)
7.16 (2.45)
Propionylcarnitine, C3 (nmole/g)
0.37 (0.12)
Butyrylcarnitine, C4 (nmole/g)
0.19 (0.11)
Valerylcarnitine, C5 (nmole/g)
0.15 (0.05)
Octanoylcarnitine, C8 (nmole/g)
0.17 (0.12)
Decanoylcarnitine, C10 (nmole/g)
0.33 (0.29)
Dodecanoylcarnitine, C12 (nmole/g)
0.21 (0.11)
Mean (SD) presented for continuous variables; F2-isoprostane composite index was calculated using all four F2-isoprostane measurements as follows: each value was standardized (divided by the standard deviation) and mean of the four standardized values was calculated for each participant.
